This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Izawa, J. I.
Right arrow Articles by Dinney, C. P.N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izawa, J. I.
Right arrow Articles by Dinney, C. P.N.
Related Collections
Right arrow Prostate Cancer
Right arrow Hematologic pathology (including blood transfusion)
CMAJ • March 6, 2001; 164 (5)
© 2001 Canadian Medical Association or its licensors

Review
Synthèse

The role of angiogenesis in prostate and other urologic cancers: a review

Jonathan I. Izawa and Colin P.N. Dinney

From the Departments of Urology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Tex.

Abstract

ANGIOGENESIS IS A PROCESS CRITICAL TO both tumour growth and metastasis. It is a dynamic integrated process involving basement membrane degradation, endothelial cell proliferation and migration, and capillary tubule formation. Under normal circumstances, the microvasculature is maintained in a quiescent state. The acquisition of the angiogenic phenotype depends on the outcome of stimulatory and inhibitory regulation by the tumour and its microenvironment. There are markers of angiogenesis that potentially could provide prognostic information in addition to that gained from conventional clinicopathologic data, and antiangiogenic therapy for urologic cancers has potential advantages over current therapeutic strategies. Promising preclinical studies have led to the initiation of phase I studies of antiangiogenic therapy in combination with chemotherapy, which may lead to novel treatments for urologic malignant tumours and may identify new intermediate markers for the response to therapy.




This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
J. Concato, D. Jain, E. Uchio, H. Risch, W. W. Li, and C. K. Wells
Molecular Markers and Death From Prostate Cancer
Ann Intern Med, May 5, 2009; 150(9): 595 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
R. W. Alfano, S. H. Leppla, S. Liu, T. H. Bugge, C. J. Meininger, T. C. Lairmore, A. F. Mulne, S. H. Davis, N. S. Duesbery, and A. E. Frankel
Matrix Metalloproteinase-Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis
Mol. Cancer Res., April 1, 2009; 7(4): 452 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
H. Hu, Y. Ran, Y. Zhang, Z. Zhou, S. J. Harris, L. Yu, L. Sun, J. Pan, J. Liu, J. Lou, et al.
Antibody Library-based Tumor Endothelial Cells Surface Proteomic Functional Screen Reveals Migration-stimulating Factor as an Anti-angiogenic Target
Mol. Cell. Proteomics, April 1, 2009; 8(4): 816 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
J. H. Wang, P. Q. Min, P. J. Wang, W. X. Cheng, X. H. Zhang, Y. Wang, X. H. Zhao, and X. Q. Mao
Dynamic CT Evaluation of Tumor Vascularity in Renal Cell Carcinoma.
Am. J. Roentgenol., May 1, 2006; 186(5): 1423 - 1430.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. M. Katona, B. L. Neubauer, P. W. Iversen, S. Zhang, L. A. Baldridge, and L. Cheng
Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors
Clin. Cancer Res., December 1, 2005; 11(23): 8358 - 8363.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Aalinkeel, M. P. N. Nair, G. Sufrin, S. D. Mahajan, K. C. Chadha, R. P. Chawda, and S. A. Schwartz
Gene Expression of Angiogenic Factors Correlates with Metastatic Potential of Prostate Cancer Cells
Cancer Res., August 1, 2004; 64(15): 5311 - 5321.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. R. Gray, W. J. Huss, J. M. Yau, L. E. Durham, E. S. Werdin, W. K. Funkhouser Jr., and G. J. Smith
Short-Term Human Prostate Primary Xenografts: An in Vivo Model of Human Prostate Cancer Vasculature and Angiogenesis
Cancer Res., March 1, 2004; 64(5): 1712 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Santos, C. Costa, S. Pereira, M. Koch, T. Amaro, F. Cardoso, T. Guimaraes, M. J. Bento, F. Lobo, S. Pinto, et al.
Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours
Ann. Onc., September 1, 2003; 14(9): 1419 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Levine, J. A. Lucci III, B. Pazdrak, J.-Z. Cheng, Y.-S. Guo, C. M. Townsend Jr., and M. R. Hellmich
Bombesin Stimulates Nuclear Factor {kappa}B Activation and Expression of Proangiogenic Factors in Prostate Cancer Cells
Cancer Res., July 1, 2003; 63(13): 3495 - 3502.
[Abstract] [Full Text] [PDF]